Total Payments
$327,910
2024 Payments
$43,294
Companies
32
Transactions
376
Medicare Patients
191
Medicare Billing
$27,944
Payment Breakdown by Category
Consulting$140,997 (43.0%)
Other$126,303 (38.5%)
Travel$44,809 (13.7%)
Food & Beverage$10,575 (3.2%)
Research$4,760 (1.5%)
Education$466.30 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $140,997 | 25 | 43.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $78,168 | 21 | 23.8% |
| Honoraria | $48,110 | 16 | 14.7% |
| Travel and Lodging | $44,809 | 84 | 13.7% |
| Food and Beverage | $10,575 | 217 | 3.2% |
| Unspecified | $4,760 | 3 | 1.5% |
| Education | $466.30 | 9 | 0.1% |
| Grant | $25.00 | 1 | 0.0% |
Payments by Type
General
$323,150
373 transactions
Research
$4,760
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $74,633 | 56 | $0 (2023) |
| CSL Behring | $52,742 | 36 | $0 (2023) |
| Shire North American Group Inc | $47,883 | 57 | $0 (2019) |
| GENZYME CORPORATION | $35,195 | 31 | $0 (2024) |
| Octapharma USA, Inc. | $32,952 | 29 | $0 (2024) |
| PFIZER INC. | $14,040 | 12 | $0 (2024) |
| Genentech USA, Inc. | $12,233 | 21 | $0 (2023) |
| BIOVERATIV THERAPEUTICS INC. | $11,317 | 22 | $0 (2019) |
| Pharmacosmos Therapeutics Inc. | $10,327 | 10 | $0 (2022) |
| Genentech, Inc. | $5,390 | 10 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $43,294 | 22 | Octapharma USA, Inc. ($18,592) |
| 2023 | $34,116 | 45 | GENZYME CORPORATION ($16,114) |
| 2022 | $15,655 | 28 | Novo Nordisk Inc ($10,919) |
| 2021 | $26,573 | 22 | CSL Behring ($10,875) |
| 2020 | $16,753 | 17 | BioMarin Pharmaceutical Inc. ($5,203) |
| 2019 | $79,462 | 113 | Novo Nordisk Inc ($38,344) |
| 2018 | $43,926 | 65 | Novo Nordisk Inc ($23,044) |
| 2017 | $68,130 | 64 | Shire North American Group Inc ($41,970) |
All Payment Transactions
376 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | PFIZER INC. | VYNDAMAX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,987.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/20/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $140.68 | General |
| 12/10/2024 | PFIZER INC. | VYNDAMAX (Drug) | Travel and Lodging | In-kind items and services | $64.78 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/06/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,887.00 | General |
| 11/20/2024 | Octapharma USA, Inc. | FIBRYGA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $18,591.88 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 10/29/2024 | Takeda Pharmaceuticals U.S.A., Inc. | VONVENDI (Biological) | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: HEMATOLOGY | ||||||
| 09/14/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $1,141.66 | General |
| 09/14/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $558.83 | General |
| 09/14/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $70.33 | General |
| 06/12/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological) | Food and Beverage | In-kind items and services | $94.35 | General |
| Category: Hematology | ||||||
| 05/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ADVATE (Biological) | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: HEMATOLOGY | ||||||
| 04/10/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $680.00 | General |
| Category: Genetic Disease | ||||||
| 02/27/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $11,532.50 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $719.38 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $400.83 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $355.35 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $110.80 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $87.41 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $72.46 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $47.90 | General |
| 02/27/2024 | GENZYME CORPORATION | — | Food and Beverage | Cash or cash equivalent | $15.51 | General |
| 01/10/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,700.00 | General |
| Category: Genetic Disease | ||||||
| 11/16/2023 | Genentech USA, Inc. | Hemlibra (Biological) | Consulting Fee | Cash or cash equivalent | $6,460.00 | General |
| Category: Hematology | ||||||
| 11/16/2023 | Genentech USA, Inc. | Hemlibra (Biological) | Travel and Lodging | Cash or cash equivalent | $645.17 | General |
| Category: Hematology | ||||||
| 11/16/2023 | Genentech USA, Inc. | Hemlibra (Biological) | Travel and Lodging | Cash or cash equivalent | $242.65 | General |
| Category: Hematology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| HEMOPHILIA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,760 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 51 | 64 | $17,804 | $7,655 |
| 2022 | 3 | 49 | 63 | $17,795 | $7,036 |
| 2021 | 3 | 57 | 65 | $19,800 | $8,863 |
| 2020 | 2 | 34 | 39 | $12,351 | $4,389 |
Total Patients
191
Total Services
231
Medicare Billing
$27,944
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 36 | 49 | $10,829 | $4,901 | 45.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $6,975 | $2,755 | 39.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 27 | 40 | $8,840 | $3,344 | 37.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $5,115 | $2,000 | 39.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 12 | $3,840 | $1,692 | 44.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 28 | 35 | $7,735 | $3,732 | 48.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 17 | 17 | $7,905 | $3,125 | 39.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 13 | $4,160 | $2,007 | 48.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 14 | 14 | $6,686 | $2,389 | 35.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 20 | 25 | $5,665 | $2,000 | 35.3% |
About Dr. Lisa Boggio, MD
Dr. Lisa Boggio, MD is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336116151.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lisa Boggio, MD has received a total of $327,910 in payments from pharmaceutical and medical device companies, with $43,294 received in 2024. These payments were reported across 376 transactions from 32 companies. The most common payment nature is "Consulting Fee" ($140,997).
As a Medicare-enrolled provider, Boggio has provided services to 191 Medicare beneficiaries, totaling 231 services with total Medicare billing of $27,944. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chicago, IL
- Active Since 03/01/2006
- Last Updated 11/16/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1336116151
Products in Payments
- Idelvion (Biological) $25,296
- Afstyla (Biological) $24,817
- FIBRYGA (Biological) $18,592
- NUWIQ (Biological) $11,560
- FITUSIRAN (Drug) $11,239
- ADVATE (Biological) $10,662
- Monoferric (Drug) $8,542
- Hemlibra (Biological) $7,441
- NovoSeven RT (Drug) $5,788
- HEMLIBRA (Biological) $5,550
- GIVLAARI (Drug) $4,923
- Albutein (Biological) $4,871
- Non-Covered Product (Drug) $4,592
- IXINITY (Drug) $4,270
- VYNDAMAX (Drug) $4,052
- Jivi (Drug) $3,329
- Alphanate (Biological) $3,273
- FERRIPROX 500 MG/1 TABLET (Drug) $3,135
- CABLIVI (Biological) $3,111
- MONOFERRIC (Drug) $1,786
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678